Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

iBio Picked Up by Goldman Small Cap Research, Jan. 5

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines the reasoning behind the coverage initiation.

 

 

"iBio's paradigm-changing platform takes the old model biotech and changes it such that revenue generation could be faster, along with lower capital costs. In our view, validation has already occurred with its relationships with and funding from DARPA and the Gates Foundation."